Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

16.53 -0.08 (-0.48%)
Streaming Delayed Price Updated: 2:34 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗
Alto Neuroscience reports a narrower-than-expected Q3 2025 loss and advances its precision psychiatry pipeline, with cash extending into 2028. 
Via Chartmill
News headline image
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Alto Neuroscience Announces $50 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug ↗
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. 
Via Stocktwits
News headline image
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Alto Neuroscience, Inc. Class Action: Levi &amp; Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi &amp; Korsinsky About Pending Class Action - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.